BALAXI PHARMACEUTICALS LIMITED

rs,

etary & Compliance Officer Encl: A/a Registered Office: Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase Ill, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096 CIN: L25191TG1942PLC12

400 billion

on . Product Sourcing Regions Balaxi aiaxi Existing/targeted markets have aggregate GDP of S 400 billion and pharma imports of S 6 billion Tfi 12 Key Milestones Started business supplying white lab

6 billion

laxi aiaxi Existing/targeted markets have aggregate GDP of S 400 billion and pharma imports of S 6 billion Tfi 12 Key Milestones Started business supplying white labelled products to customers in Af

INR 47.57 crore

nduras and El Salvador Successfully completed fund raising exercise through Preferential issue — INR 47.57 crore Capex plans — Established Company’s first pharma formulation manufacturing facility in Hyderabad

70.74 crore

ic initiatives, and continued execution on our long-term roadmap. The Company recorded revenue of X70.74 crore in Q1 FY26, reflecting a growth of 8% YoY, supported by stable demand and operational execution ac

8%

long-term roadmap. The Company recorded revenue of X70.74 crore in Q1 FY26, reflecting a growth of 8% YoY, supported by stable demand and operational execution across markets. Gross profit margin rema

44%

by stable demand and operational execution across markets. Gross profit margin remained healthy at 44%, underscoring the strength of our branded generic business. However, the bottom line declined shar

329 lakh

scoring the strength of our branded generic business. However, the bottom line declined sharply to 329 lakhs (vs ¥6.48 crore in Q1 FY25), primarily due to increased in operational cost — driven by one-time

6.48 crore

rength of our branded generic business. However, the bottom line declined sharply to 329 lakhs (vs ¥6.48 crore in Q1 FY25), primarily due to increased in operational cost — driven by one-time write-offs under

41.9%

in Profit After Tax PAT Margin % Earning Per Share (in Rs.) Balaxi Q1 FY25 65.62 27.48 41.9% 10.08 15.4% 6.48 9.9% 1.23 Pharma Product Mix— Q1 FY26 Geographies Products m Africa

15.4%

ter Tax PAT Margin % Earning Per Share (in Rs.) Balaxi Q1 FY25 65.62 27.48 41.9% 10.08 15.4% 6.48 9.9% 1.23 Pharma Product Mix— Q1 FY26 Geographies Products m Africa* u LATM**

9.9%

Margin % Earning Per Share (in Rs.) Balaxi Q1 FY25 65.62 27.48 41.9% 10.08 15.4% 6.48 9.9% 1.23 Pharma Product Mix— Q1 FY26 Geographies Products m Africa* u LATM** = Branded =

“Over the medium term, Balaxi sees several new market opportunities opening up for its product lines.”

“Stickler for well-defined systems and processes Initiated and leads the consumer products business FINANCIAL HIGHLIGHTS Balaxi “Q1 FY26, a quarter marked by steady growth, ongoing investments in strategic initiatives, and continued execution on our long-term roadmap.”

“The Company recorded revenue of X70.74 crore in Q1 FY26, reflecting a growth of 8% YoY, supported by stable demand and operational execution across markets.”

“However, the bottom line declined sharply to 329 lakhs (vs ¥6.48 crore in Q1 FY25), primarily due to increased in operational cost — driven by one-time write-offs under administrative expenses, and the recently subsidiarized Nicaragua business which is yet to reach break-even.”

Registered Office

1

Email

1

Expansion initiated

1

Registered Office

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase Ill, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096 CIN: L25191TG1942PLC121598 Phone: +91 40 23555300 |

Email

info@balaxi.in | Website: www.balaxipharma.in Balaxi Pharmaceuticals Limited Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation ' Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Balaxi Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. Balaxi 04 Corporate Snapshot 17 Financial Highlights 23 Strategic Roadmap Balaxi Branded IPR-based pharma company Frontier markets leadership in Latin America and Africa Vast portfolio across diverse therapeut

Expansion initiated

Ecuador, Chile (Latin America) 929 product registrations in Seven countries 300+ registrations submitted or in the pipeline Established the Company’s first pharmaceutical formulation facility in Hyderabad Successful process being replicated in other frontier markets; expansion plans in other global markets over near to medium term Centralized digital procurement, regulatory management and customized CRM tools Key Success Factors Market Selection Methodology = Focus on countries with high-potential economic growth framework = |dentify non-English speaking countries with similar characteristics = Low competitive intensity and potential to establish top-2 position = On-ground feedback mechanism allows deep understanding of demand dynamics = As population crosses prosperity thresholds, healthcare spends expand exponentially Human Capital Management = Established unique ecosystem of 100+ Indian expatriates in operating geographies = Financial security ecosystem for key personnel, creating a